CR6491A - HIV IMMUNOGENIC COMPOSITIONS AND METHODS - Google Patents

HIV IMMUNOGENIC COMPOSITIONS AND METHODS

Info

Publication number
CR6491A
CR6491A CR6491A CR6491A CR6491A CR 6491 A CR6491 A CR 6491A CR 6491 A CR6491 A CR 6491A CR 6491 A CR6491 A CR 6491A CR 6491 A CR6491 A CR 6491A
Authority
CR
Costa Rica
Prior art keywords
hiv
immunogenic compositions
antigen
mammal
methods
Prior art date
Application number
CR6491A
Other languages
Spanish (es)
Inventor
B Moss Ronald
Original Assignee
Inmune Response Corp
Abr Llc
Acumer Investigacion Desarrollo S L
Antonio Jose De Jesus De San Juan Bosco Echevarria Parres
Dystar Textilfarben Gmbh Y Co Deutschland Kg
Eco Flora S A
John Larry Sanders
Ranka Seema Ajay
Sanofi Aventis
Smithjkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inmune Response Corp, Abr Llc, Acumer Investigacion Desarrollo S L, Antonio Jose De Jesus De San Juan Bosco Echevarria Parres, Dystar Textilfarben Gmbh Y Co Deutschland Kg, Eco Flora S A, John Larry Sanders, Ranka Seema Ajay, Sanofi Aventis, Smithjkline Beecham Corp filed Critical Inmune Response Corp
Publication of CR6491A publication Critical patent/CR6491A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención ofrece composiciones inmugénicas que incrementan los niveles de B- quimiocina en un mamífero.Las composiciones inmugénicas contienen un antígeno de VIH, una mólecula de ácido nucleico aislada que contiene una secuencia inmunoestimuladora (ISS) y un adyuvnate. El antígeno de VIH puede ser un virus de VIH entero muerto sin la proteina de envoltura externa gp120. Alternativamente, el antígeno de VIH puede ser un virus de VIH entero muerto, o bien un antígeno p24. Se proporciona también un método para inhibir el SIDA, mediante el incremento de la producción de B-quimiciona en el mamífero mediante la administración al mamífero de una composición inmunogénica que contiene un antígeno de VIH, una molécula de ácido nucleico aislada que contiene una secuencia inmunoestimuladora (ISS) y un adyuvante.The invention offers immunogenic compositions that increase levels of B-chemokine in a mammal. Immunogenic compositions contain an HIV antigen, an isolated nucleic acid molecule that contains an immunostimulatory sequence (ISS) and an adjuvant. The HIV antigen can be a dead whole HIV virus without the outer envelope protein gp120. Alternatively, the HIV antigen can be a dead whole HIV virus, or a p24 antigen. A method for inhibiting AIDS is also provided by increasing the production of B-chemocyte in the mammal by administering to the mammal an immunogenic composition containing an HIV antigen, an isolated nucleic acid molecule containing an immunostimulatory sequence. (ISS) and an adjuvant.

CR6491A 1999-05-06 2001-10-25 HIV IMMUNOGENIC COMPOSITIONS AND METHODS CR6491A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13276299P 1999-05-06 1999-05-06
US15066799P 1999-08-25 1999-08-25

Publications (1)

Publication Number Publication Date
CR6491A true CR6491A (en) 2005-05-31

Family

ID=26830710

Family Applications (1)

Application Number Title Priority Date Filing Date
CR6491A CR6491A (en) 1999-05-06 2001-10-25 HIV IMMUNOGENIC COMPOSITIONS AND METHODS

Country Status (8)

Country Link
EP (1) EP1176978A2 (en)
AP (1) AP1891A (en)
AU (1) AU4992900A (en)
BR (1) BR0010323A (en)
CA (1) CA2372960C (en)
CR (1) CR6491A (en)
OA (1) OA11937A (en)
WO (1) WO2000067787A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1077722B1 (en) 1998-05-22 2006-08-09 Ottawa Health Research Institute Methods and products for inducing mucosal immunity
CA2358385C (en) 1998-12-31 2013-08-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US7776343B1 (en) 1999-02-17 2010-08-17 Csl Limited Immunogenic complexes and methods relating thereto
DE60023300T2 (en) * 1999-06-29 2006-07-06 Glaxosmithkline Biologicals S.A. USE OF CPG AS ADJUVANS FOR HIV PULP
ES2347525T3 (en) 2000-12-27 2010-11-02 Dynavax Technologies Corporation IMMUNOMODULATING POLINUCLEOTIDES AND METHODS FOR USERS.
SG152045A1 (en) * 2001-01-26 2009-05-29 Immune Response Corp Inc Method for treating an hiv-infected individual by combining immunization with structured interruption of anti-retroviral treatment
EP2423335B1 (en) 2001-06-21 2014-05-14 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same
EP1411770A4 (en) 2001-07-05 2006-05-10 Chiron Corp Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP1446162B1 (en) 2001-08-17 2008-10-15 Coley Pharmaceutical GmbH Combination motif immune stimulatory oligonucleotides with improved activity
AR045702A1 (en) 2001-10-03 2005-11-09 Chiron Corp COMPOSITIONS OF ASSISTANTS.
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
JP2005532067A (en) * 2002-07-03 2005-10-27 コーリー ファーマシューティカル グループ，インコーポレイテッド Nucleic acid composition for stimulating immune response
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
JP2006515277A (en) 2002-10-29 2006-05-25 コーリー ファーマシューティカル グループ， リミテッド Methods and products for treatment and prevention of hepatitis C virus infection
JP2006512927A (en) 2002-12-11 2006-04-20 コーリー ファーマシューティカル グループ，インコーポレイテッド 5 'CPG nucleic acids and methods of use thereof
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
KR101309501B1 (en) 2002-12-23 2013-09-24 다이나박스 테크놀로지 코퍼레이션 Immunostimulatory sequence oligonucleotides and methods of using the same
WO2005021726A2 (en) * 2003-08-28 2005-03-10 The Immune Response Corporation Immunogenic hiv compositions and related methods
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
PT2078080E (en) 2006-09-27 2015-09-18 Coley Pharm Gmbh Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
WO2010051820A1 (en) * 2008-11-10 2010-05-14 Aarhus Universitet Multiplexed cytokine vaccination
US9636410B2 (en) 2011-07-06 2017-05-02 Glaxosmithkline Biologicals Sa Cationic oil-in-water emulsions
US9655845B2 (en) 2011-07-06 2017-05-23 Glaxosmithkline Biologicals, S.A. Oil-in-water emulsions that contain nucleic acids

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1005368B1 (en) * 1997-03-10 2009-09-02 Ottawa Hospital Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide in combination with alum as adjuvants
ATE252596T1 (en) * 1997-06-06 2003-11-15 Dynavax Tech Corp IMMUNO-STIMULATING OLIGONUCLEOTIDES, COMPOSITIONS THEREOF, AND METHODS OF USE THEREOF

Also Published As

Publication number Publication date
AU4992900A (en) 2000-11-21
AP2001002300A0 (en) 2001-12-31
WO2000067787A3 (en) 2001-04-26
AP1891A (en) 2008-09-23
BR0010323A (en) 2002-01-08
OA11937A (en) 2006-04-12
WO2000067787A2 (en) 2000-11-16
CA2372960C (en) 2006-03-28
CA2372960A1 (en) 2000-11-16
EP1176978A2 (en) 2002-02-06

Similar Documents

Publication Publication Date Title
CR6491A (en) HIV IMMUNOGENIC COMPOSITIONS AND METHODS
ATE331530T1 (en) PROTEASOME INFLUENZA VIRUS VACCINE COMPOSITION G
CO5680456A2 (en) COMPOSITIONS OF VACCINES THAT INCLUDE LIPOOLIGOSACARIDS OF IMMUNOTIPE L2 AND / OR L3 FROM LGTB-NEISSERIA MINIGITIDIS
ES2129386T1 (en) INFLUENZA VACCINE.
PE20071098A1 (en) IMMUGENIC COMPOSITION CONTAINING AS ADJUVANTS A SAPONIN AND A POLYSACCHARIDE
DK0778888T3 (en) Antigen-labeled non-infectious retrovirus-like particle
BR0107679A (en) Outer membrane vesicle (omv) vaccine comprising neisseria meningitidis serum group b outer membrane proteins
ES2421543T3 (en) Method for the preparation of PRRS viruses and proteins, and diagnostic test kits for detection
MY136081A (en) Modified hiv - 1gag p17 peptide and immunogenic composition
AR050102A1 (en) HIV FUSION POLIPEPTIDES FOR AIDS PREVENTION AND / OR TREATMENT
ATA155598A (en) NEW INFLUENCE VIRUS VACCINE COMPOSITION
EA200201271A1 (en) INHIBITORS 11-BETA-HYDROXYSTEROID DEGYDROGENASE TYPE 1
MX9306841A (en) UREASE BASED VACCINE AGAINST HELICOBACTER INFECTION IN MAMMALS.
DK1104306T3 (en) Preparations of CpG and Saponin Adjuvants and Methods for Using Them
DE68927348D1 (en) ARTIFICIAL VACCINE AGAINST AIDS VIRUS
ES2140076T3 (en) VACCINES CONTAINING A SAPONIN AND A STEROL.
MY129263A (en) Vaccine composition
CR8251A (en) IMMUNOGENIC HIV COMPOSITIONS AND RELATED METHODS
ECSP045300A (en) VIRAL ANTIGENS
HUP0002322A2 (en) Multivalent vaccine composition with mixed carrier
DK1326636T3 (en) vaccine Composition
ES8603756A1 (en) Immunogenic composition comprising live encysted protozoa.
HK1044778A1 (en) Hiv-peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv hiv
WO2005013918A3 (en) Compositions, methods and kits relating to poxvirus subunit vaccines
EA200400690A1 (en) NUCLEOSIDES, THEIR PREPARATIONS AND THEIR APPLICATION AS VIRAL RNA POLYMERASE INHIBITORS

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)